ClinicalTrials.gg
Sign In
DrugBiological

G250 monoclonal antibody clinical trials

Also written girentuximab.

studies test it
5
open now
0
in phase 3
2
first study started
2004

How each study uses G250 monoclonal antibody is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Brand

rencarex
1

Development codes

cG250
1

Other names

girentuximab
2

Studies by the year they started

5 studies that test it; most in 2004 (1)

Studies that test G250 monoclonal antibody, by start year
YearStudies
20041
20051
20071
20081
20151

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
2
Phase 3
2
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Carcinoma, Renal Cell
4
Kidney Neoplasms
1

Who runs them

Industry 1 · Other 4

Ludwig Institute for Cancer Research (2) · Radboud University Medical Center (2) · Heidelberg Pharma AG (1)

Often tested with

Tested in the same studies.

Lutetium Lu-177 Girentuximab (1) · Sorafenib (1) · Bevacizumab (1)

Studies

Open first, then newest update. How each study uses G250 monoclonal antibody is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 5